A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice
Unable to display preview. Download preview PDF.
We thank Dr. Bart L. Haagmans and Dr. Ron A.M. Fouchier (Erasmus MC, Rotterdam, the Netherlands) for providing MERSCoV (isolate hCoV-EMC/2012). This work was supported by the National Key Research and Development Program of China (2016YFD0500300 to Wenjie Tan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Agrawal, A.S., Ying, T., Tao, X., Garron, T., Algaissi, A., Wang, Y., Wang, L., Peng, B.H., Jiang, S., Dimitrov, D.S., et al. (2016). Passive transfer of A germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal middle east respiratory syndrome coronavirus infection. Sci Rep 6, 31629.CrossRefPubMedPubMedCentralGoogle Scholar
- Qiu, H., Sun, S., Xiao, H., Feng, J., Guo, Y., Tai, W., Wang, Y., Du, L., Zhao, G., and Zhou, Y. (2016). Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral Res 132, 141–148.CrossRefPubMedPubMedCentralGoogle Scholar
- Zhao, G., Du, L., Ma, C., Li, Y., Li, L., Poon, V.K., Wang, L., Yu, F., Zheng, B.J., Jiang, S., et al. (2013). A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J 10, 266.CrossRefPubMedPubMedCentralGoogle Scholar